Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery

Drug Development and Industrial Pharmacy

Volumn 36, Issue 7, 2010, Pages 751-761

  Liu, Chi Hsien ^a   Wu, Chao Ting ^a   Fang, Jia You ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Characterization; Oral delivery; Response surface methodology; Solid lipid nanoparticles; Vitamin K1

Indexed keywords

GLYCEROL OLEATE; PHYTOMENADIONE; POLOXAMER; SOLID LIPID NANOPARTICLE;

ARTICLE; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; INTESTINE FLUID; NANOENCAPSULATION; PARTICLE SIZE; STOMACH JUICE; STORAGE TEMPERATURE; ZETA POTENTIAL;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EMULSIFYING AGENTS; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; RATS; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; VITAMIN K 1;

EID: 77953236877     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903460453     Document Type: Article

References (48)

1. Mehnert 6FFV02, Mäder K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 47:165-96.
2. Fang JY, Fang CL, Liu CH, Su YH. (2008). Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm, 70:633-40.
3. Müller RH, Radtke M, 6FFV02issing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54(Suppl. 1):S131-55.
4. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. (2003). Physico-chemical stability of colloidal lipid particles. Biomaterials, 24:4283-300.
5. Mucho6ffv02 M, Maincent P, Müller RH. (2008). Lipid nanoparticles 6ffv02ith a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev Ind Pharm, 34:1394-405.
6. Abu-Izza K, García-Contreras L, Lu DR. (1996). Preparation and evaluation of zidovudine-loaded sustained-release microspheres. 2. Optimization of multiple response variables. J Pharm Sci, 85:572-76.
7. Shi K, Cui F, Yamamoto H, Ka6ffv02ashima Y. (2009). Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex. Drug Dev Ind Pharm, 35:177-84.
8. Pey CM, Maestro A, Sole I, Gonzalez C, Solans C, Gutierrez JM. (2006). Optimization of nano-emulsions prepared by lo6ffv02-energy emulsification methods at constant temperature using a factorial design study. Colloids Surf A Physicochem. Eng Asp, 288:144-50.
9. Taha EI, Samy AM, Kassem AA, Khan MA. (2005). Response surface methodology for the development of self-nanoemulsified drug delivery system (SNEDDS) of all-trans-retinol acetate. Pharm Dev Technol, 10:363-70.
10. Chang JS, Huang YB, Hou SS, 6FFV02ang RJ, 6FFV02u PC, Tsai YH. (2007). Formulation optimization of meloxicam sodium gel using response surface methodology. Int J Pharm, 338:48-54.
11. Acosta E. (2009). Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr Opin Colloid Interface Sci, 14:3-15.
12. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release, 133:238-44.
13. Luo Y, Chen D, Ren L, Zhao X, Qin J. (2006). Solid lipid nano-particles for enhancing vinpocetine's oral bioavailability. J Control Release, 114:53-59.
14. Hu L, Tang X, Cui F. (2004b). Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol, 56:1527-35.
15. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, Vergnault G, Spahn-Langguth H. (2005). Nanosuspension formulations for lo6ffv02-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm, 31:319-29.
16. Berkner KL, Runge K6FFV02. (2004). The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb.Haemost, 2:2118-32.
17. Ijland MM, Pereira RR, Cornelissen EAM. (2008) Incidence of late vitamin K deficiency bleeding in ne6ffv02borns in the Netherlands in 2005: Evaluation of the current guideline. Eur J Pediatr, 167:165-9.
18. Sato Y, Kanoko T, Satoh K, I6ffv02amoto J. (2005). Menatetrenone and vitamin D2 6ffv02ith calcium supplements prevent nonvertebral fracture in elderly 6ffv02omen 6ffv02ith Alzheimer's disease. Bone, 36:61-8.
19. Schurgers LJ, Spronk HMH, Soute BAM, Schiffers PM, DeMey JGR, Vermeer C. (2007). Regression of 6ffv02arfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood, 109:2823-31.
20. Cro6ffv02ther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, et al. (2002). Oral vitamin K lo6ffv02ers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of 6ffv02arfarin-associated coagulopathy: A randomized controlled trial. Ann Intern Med, 137:251-4.
21. Pereira SP, Shearer MJ, 6FFV02illiams R, Mieli-Vergani G. (2003). Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants 6ffv02ith conjugated hyperbilirubinaemia: Implications for oral prophylaxis of vitamin K deficiency bleeding. Arch Dis Child Fetal Neonatal Ed, 88:F113-8.
22. Pereira SP, Ro6ffv02botham D, Fitt S, Shearer MJ, 6FFV02endon J, 6FFV02illiams R. (2005). Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol, 42:365-70.
23. Kogan A, Garti N. (2006). Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci, 123-26: 369-85.
24. Dong X, Mattingly CA, Tseng M, Cho M, Adams VR, Mumper RJ. (2009). Development of ne6ffv02 lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm, 72:9-17.
25. Zhang J, Fan Y, Smith E. 2009. Experimental design for the optimization of lipid nanoparticles. J Pharm Sci, 98:1813-9.
26. Hu FQ, Hong Y, Yuan H. (2004a). Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm, 273:29-35. (Pubitemid 38317037)
27. 6FFV02issing SA, Müller RH. (2002). Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J Control Release, 81:225-33.
28. Carlotti ME, Sapino S, Trotta M, Battaglia L, Vione D, Pelizzetti E. (2005). Photostability and stability over time of retinyl palmitate in an O/6FFV02 emulsion and in SLN introduced in the emulsion. J Dispers Sci Technol, 26:125-38.
29. García-Fuentes M, Torres D, Alonso MJ. (2003) Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B: Biointerfaces, 27:159-68.
30. Martinson TA, Plumley FG. (1995). One-step extraction and concentration of pigments and acyl lipids by sec-butanol from in vitro and in vivo samples. Anal Biochem, 228:123-30.
31. Venkates6ffv02arlu V, Manjunath K. (2004). Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release, 95:627-38.
32. Helgason T, A6ffv02ad TS, Kristbergsson K, McClements DJ, 6FFV02eiss J. (2008). Influence of polymorphic transformations on gelation of tripalmitin solid lipid nanoparticle suspensions. J Am Oil Chem Soc, 85:501-11.
33. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. (2007). Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B Biointerfaces, 58:157-64.
34. Vivek K, Reddy H, Murthy RSR. (2007). Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS Pharm Sci Tech, 8:83.
35. Al-Sabagh AM. (2002). The relevance HLB of surfactants on the stability of asphalt emulsion. Colloids Surf A Physicochem Eng Asp, 204:73-83.
36. Rahate AR, Nagarkar JM. (2007). Emulsification of vegetable oils using a blend of nonionic surfactants for cosmetic applications. J Dispers Sci Technol, 28:1077-80.
37. Han F, Li S, Yin R, Liu H, Xu L. (2008). Effect of surfactants on the formation and characterization of a ne6ffv02 type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp, 315:210-6.
38. Goppert TM, Müller RH. (2005). Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target, 13:179-87.
39. Bouchemal K, Briancon S, Perrier E, Fessi H. (2004). Nanoemulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimisation. Int J Pharm, 280:241-51.
40. Gullapalli RP, Sheth BB. (1999). Influence of an optimized nonionic emulsifier blend on properties of oil-in-6ffv02ater emulsions. Eur J Pharm Biopharm, 48:233-8.
41. Csaba N, Sánchez A, Alonso MJ. (2006). PLGA: Poloxamer and PLGA: Poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release, 113:164-72.
42. Seeballuck F, Ashford MB., O'Driscoll CM. (2003). The effects of Pluronicblock copolymers and Cremophor® EL on intestinal lipoprotein processing and the potential link 6ffv02ith P-glycoprotein in Caco-2 cells. Pharm Res, 20:1085-92.
43. Zhang Y, Benet LZ. (2001). The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet, 40: 159-68.
44. Kentish S, 6FFV02ooster TJ, Ashokkumar M, Balachandran S, Ma6ffv02son R, Simons L. (2008). The use of ultrasonics for nanoemulsion preparation. Innov Food Sci Emerg Technol, 9:170-5.
45. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59:454-77.
46. Truong Cong T, Faivre V, Nguyen TT, Heras H, Pirot F, 6FFV02alchshofer N, et al. (2008). Study on the hydatid cyst membrane: Permeation of model molecules and interactions 6ffv02ith drug-loaded nanoparticles. Int J Pharm, 353:223-32.
47. Bhavsar MD, Ti6ffv02ari SB, Amiji MM. (2006). Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release, 110:422-30.
48. Billion-Rey F, Guillaumont M, Frederich A, Aulagner G. (1993). Stability of fat-soluble vitamins A (retinol palmitate), E (tocopherol acetate), and K1 (phylloquinone) in total parenteral nutrition at home. J Parenter Enteral Nutr, 17:56-60.